SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending with intense anticipation for its Phase 3 REGAL trial results, as the extended timeline is widely seen by the community as a positive indicator of 'curative outcomes' and a potential buyout. Investors are largely dismissing bearish sentiment and focusing on increasing institutional interest and the transformative potential of the company's dual cancer platforms.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending following multiple analyst upgrades with significantly higher price targets and anticipation around management's comments on stabilizing the BetterHelp segment and addressing debt. The community is actively debating its extreme undervaluation compared to sector peers and its strong free cash flow, fueling speculation of a potential short squeeze amid optimism for its global virtual care platform and AI initiatives.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending after reporting a significant Q4 earnings beat driven by strong MIPLYFFA sales, which is signaling a shift to profitability and sparking community discussions about its re-rating potential and a possible short squeeze.

Crane Harbor Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 2, 2025 and is headquartered in Philadelphia, PA.

Crane Harbor Acquisition Corp. - Ordinary Shares - Class A

Crane Harbor Acquisition Corp.

CHAC is trending as its merger target, Xanadu Quantum Technologies, announced a significant collaboration with AMD to accelerate quantum computing for aerospace and engineering, fueling community excitement over its real-world applications and strong client roster. Investors are actively watching the anticipated merger, with many adding the pure-play photonic quantum computing leader to their watchlists and discussing its potential compared to past successful SPACs in the burgeoning sector.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending due to President Trump's public statements declaring the Iran war "very complete" and his subsequent news conference, which is sparking immediate market conversation around oil prices and stability; however, community perspectives are divided on the actual resolution and its broader implications.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's is trending following a mixed earnings report that saw an EPS beat but a revenue miss and cautious forward guidance, sparking debate among investors. Bulls are highlighting strengthened cash flow and the company's underlying real estate value, while bears point to soft sales and the challenging retail landscape, all amplified by significant short interest.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas (ONDS) is actively discussed after announcing a merger with U.S. defense prime contractor Mistral Inc., a move many view as a transformative step providing direct access to significant Department of Defense programs and expanding its role in the autonomous defense market. While bulls are enthusiastic about this strategic positioning, community dialogue also reflects concerns regarding potential share dilution from the all-stock deal and its immediate impact on stock performance ahead of upcoming earnings.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is actively discussed amid conflicting reports on the Middle East conflict; bulls eye a "Trump pump" after claims of the war being "pretty much done," while bears highlight rising oil prices and Iranian denials, fueling concerns of manipulation and a market reversal.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending due to a bullish analyst upgrade and the upcoming R2 vehicle reveal, fueling community debate on its path to profitability and scalability, especially as rising oil prices present both opportunities and challenges for the broader EV sector.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending following its announcement of a proposed convertible senior notes offering, which has sparked community concern over potential dilution and questions regarding management's capital strategy despite significant existing cash reserves. Many are expressing frustration, especially in contrast to positive developments from its partner, Vertex Pharmaceuticals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates

Shares of Optinose, Inc. (OPTN) rocketed about 55% on Thursday after privately held Paratek Pharmaceuticals <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.optinose.com/news-releases/news-release-details/paratek-pharmaceuticals-acquire-optinose-creating-significant">announced</a> that it would buy the company for up to $330 million.The two companies have entered into a definitive merger agreement, under which Paratek will acquire Optinose and its product XHANCE, a drug-device combination product approved for the treatment of Chronic rhinosinusitis.Paratek will acquire Optinose's outstanding shares for $9 apiece in cash, representing a 50% premium to Optinose’s closing trading price of $6 on March 19, and up to $5 per share in contingent value rights (CVRs) if XHANCE achieves certain net revenue milestones.Paratek said in a statement that the boards of both companies have unanimously approved the transaction. It added that the transaction is expected to close as early as mid-2025, subject to customary closing conditions and approval by Optinose shareholders.Upon completion of the transaction, Optinose will be delisted from the NASDAQ Global market.Following the announcement, Optinose also <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.optinose.com/news-releases/news-release-details/optinose-cancels-fourth-quarter-and-full-year-2024-earnings-call">canceled</a> its earnings call for the fourth quarter of 2024, which was originally scheduled for March 20.Optinose CEO Ramy Mahmoud said that Paratek, with its commercial and medical capabilities, has the potential to increase awareness for Optinose’s XHANCE.“We are excited about the many ways in which this transaction creates opportunities for XHANCE to help more patients achieve better symptom control while creating near- and long-term value for Optinose's shareholders," he said.Paratek, meanwhile, said that the acquisition will help the company expand its portfolio.On Stocktwits, retail investor sentiment flipped from ‘extremely bearish’ to ‘extremely bullish’ (100/100) territory within the past 24 hours, coupled with ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:810/181;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_03_20_115139_png_df0e5340e2.webp" alt="Optinose’s Sentiment Meter and Message Volume as of 11:50 a.m. ET on March 20, 2025 | Source: Stocktwits" width="810" height="181"><figcaption>Optinose’s Sentiment Meter and Message Volume as of 11:50 a.m. ET on March 20, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/OPTN">Optinose shares</a> are up over 38% in 2025 but have lost over 60% in the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/geo-stock-rises-on-ice-contract/ch7Nru4RbPQ">GEO Stock Rises On Immigration And Customs Contract With Annualized Revenue Potential Of $70M: Retail’s On The Fence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail investors on Stocktwits — where Altimmune has over 36,000 followers — have long speculated that the company could be a takeover target. | Image source: Getty Images

Optinose Shares Soar After Merger Agreement With Paratek Pharmaceuticals: Retail Sentiment Takes Flight 

Paratek will acquire Optniose's outstanding shares for $9 apiece in cash, representing a 50% premium to the stock’s closing trading price of $6 on March 19.

Equity

Paratek will acquire Optinose's outstanding shares for $9 apiece in cash, representing a 50% premium to the stock’s closing trading price of $6 on March 19, and up to $5 per share in contingent value rights if XHANCE achieves certain net revenue milestones.


OPTN
OptiNose Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest OPTN News

OPTNOptiNose Inc